Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
39 people get MKGAY.PK articles and Market Currents by email alert.
Get email alerts on MKGAY.PK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
Dr. Reddy's And Merck Serono Partner On BiosimilarsThe Burrill Report • Sun, Jun 10, 2012 -
-
-
Putting Biotechs Under the MicroscopeMorningstar • Fri, Mar 11, 2011 -
-
-
-
-
Japan’s Otsuka Plans Largest Biotech IPO in the WorldThe Burrill Report • Sun, Nov 14, 2010
-
-
To learn more about Seeking Alpha Pro, click here.
-
EMD Serono Snags US license for Tesamorelin From TheratechnologiesEben Tessari • Fri, Oct 31, 2008
-
-
-
-
-
-
-
-
-
-
Dr. Reddy's And Merck Serono Partner On BiosimilarsThe Burrill Report • Sun, Jun 10, 2012
-
-
-
Putting Biotechs Under the MicroscopeMorningstar • Fri, Mar 11, 2011
-
-
-
-
-
Japan’s Otsuka Plans Largest Biotech IPO in the WorldThe Burrill Report • Sun, Nov 14, 2010
-
-
There are no Transcripts on MKGAY.PK.
There are no News articles on MKGAY.PK.
MKGAY.PK vs. ETF Alternatives
Company Description
Currently, there's no company description for MKGAY.PK.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, December 19, 2012, 8:39 AM Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) Comment! [On the Move, Healthcare]
- Tuesday, October 16, 2012, 9:01 AM Threshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase III trial of TH-302 for the treatment of pancreatic cancer. The study will be conducted by Germany's Merck, Threshold's partner in the development of TH-302. (PR) Comment! [Healthcare, On the Move]
- Friday, November 18, 2011, 3:55 PM ADRs of German chemical and pharmaceutical maker Merck KGaA (MKGAY.PK +0.7%) get a lift after receiving a positive opinion from a committee of the European Medicines Agency for its application to extend the indication of Rebif, its leading treatment for relapsing forms of multiple sclerosis. Comment! [Global & FX, Healthcare, On the Move]
- Wednesday, July 27, 2011, 3:09 AM Merck KGaA (MKGAF.PK) reports a Q2 net EPS loss of €0.40 ($0.58), vs. profit of €0.84 a year earlier. Revenue +16% to €2.56B. For 2011, Merck expects operating profit of about €1B, below guidance given in April, due to one-time adjustments. 2 Comments [Earnings, Healthcare]
There are no StockTalks on this stock yet.